Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
Uložené v:
| Názov: | Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer |
|---|---|
| Autori: | Ozkanli, Gulhan, Duman, Berna Bozkurt, Aydin, Dincer, Dulgar, Ozgecan, Er, Muhammed Muhiddin, Teker, Fatih, Yavuzsen, Tugba, Aykan, Musa Baris, Inal, Ali, Iriagac, Yakup, Kalkan, Nurhan Onal, Keser, Murat, Kut, Engin, Bilgin, Burak, Karaoglanoglu, Muge, Ozdemir, Ozlem, Turhal, Nazim Serdar, Karadurmus, Nuri, Yalcin, Bulent, Sendur, Mehmet Ali Nahit, Çakan Demirel, Burçin, Paydas, Semra, Kahraman, Seda, Erul, Enes, Seyyar, Mustafa, Gümüşay, Özge, Bayram, Ertuğrul, Acar, Ömer, Aksoy, Sercan, Baytemur, Naziyet Kose, Sahin, Elif, Cabuk, Devrim, Basaran, Gül, Guven, Deniz Can, Erdogan, Atike Pinar, Demirci, Umut, Yasar, Alper, Bayoglu, Ibrahim Vedat, Hizal, Mutlu, Gulbagci, Burcu, Paksoy, Nail, Yilmaz, Funda, Dogan, Ozlem, Orhan, Sibel Oyucu, Kayikcioglu, Erkan, Aytac, Ali, Unal, Olcun Umit, Demir, Hacer, Erol, Cihan, Selcukbiricik, Fatih, Sakalar, Teoman, Sunar, Veli, Keskinkilic, Merve, Mocan, Eda Eylemer, Aydin, Esra, Yucel, Hakan, Isik, Deniz, Eren, Onder, Uluc, Basak Oyan, Ozcelik, Melike, Hacibekiroglu, Ilhan, Aydiner, Adnan, Oksuzoglu, Berna, Cilbir, Ebru, Cubukcu, Erdem, Cetin, Bulent, Oktay, Esin, Okutur, Sadi Kerem, Yildirim, Nilgun, Alkan, Ali, Aksoy, Asude, Karakas, Yusuf, Yaren, Arzu |
| Informácie o vydavateľovi: | Future Medicine Ltd |
| Rok vydania: | 2023 |
| Zbierka: | Pamukkale University Repository / Pamukkale Üniversitesi Açık Erişim Arşivi |
| Predmety: | CDK 4, 6 inhibitors, HER2-negative metastatic breast cancer, HR-positive, letrozole |
| Popis: | Article; Early Access ; Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results ; conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference. |
| Druh dokumentu: | article in journal/newspaper |
| Jazyk: | English |
| Relation: | Future Oncology; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://hdl.handle.net/11499/51149; WOS:000991646700001 |
| DOI: | 10.2217/fon-2022-1287 |
| Dostupnosť: | https://hdl.handle.net/11499/51149 https://doi.org/10.2217/fon-2022-1287 |
| Rights: | none |
| Prístupové číslo: | edsbas.BA24BFA2 |
| Databáza: | BASE |
Nájsť tento článok vo Web of Science | Abstrakt: | Article; Early Access ; Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results ; conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference. |
|---|---|
| DOI: | 10.2217/fon-2022-1287 |